Recommendations
Free Ebook
Latest News
Site Features
Psoriasis
Study Shows Twice Weekly Etanercept (Enbrel) Clears Psoriasis Lesions More Quickly Than Once Weekly Treatment
Initial treatment with twice weekly etanercept (Enbrel), a tumour necrosis factor antagonist, achieves more rapid clearance of skin lesions than once weekly treatment in patients with active psoriasis and psoriatic arthritis, according to results from the PRESTA study reported recently in the British Medical Journal…
Also tagged Arthritis, British Medical Journal, Enbrel, Etanercept, Factor Antagonist, Initial Treatment, Psoriasis Arthritis, Psoriatic Arthritis, Rapid Clearance, Skin Lesions, Skin Treatment, Tumour Necrosis Factor
STELARA(TM) Shows Greater Efficacy Than Etanercept For Treatment Of Moderate To Severe Plaque Psoriasis
Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear in The New England Journal of Medicine. The results showed a significantly higher clinical response with both doses of STELARA than with etanercept over a 12-week [...]
Also tagged Clinical Response, Efficacy, Enbrel, England Journal Of Medicine, Etanercept, International Phase, Journal Of Medicine, Medicine, New England, New England Journal, New England Journal Of Medicine, New Medicine, Phase 3, Plaque Psoriasis
VBL Therapeutics Initiates Phase 2 Clinical Trial Of VB-201 In Patients With Psoriasis
VBL Therapeutics announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis…
Also tagged Clinical Trial, Efficacy, Immune Response, Initiation, Lead Compound, Lead Treatment, Phase 2, Reduce Inflammation, Safety Study, Vb
InNexus Biotechnology Develops New Psoriasis Product Based On Its Skin Permeating Antibody Technology
InNexus Biotechnology Inc. (TSX.V: IXS) , a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology…
Also tagged Antibodies, Antibody Technology, Biotechnology, Drug Development Company, Dynamic Cross, Innexus Biotechnology Inc, New Skin, Next Generation, Tsx
Psoriasis: Effects Don’t Always Stop With The Skin
Psoriasis, a chronic disease that causes red, raised patches of skin, is increasingly seen as a systemic disease with links to arthritis and cardiovascular disease. The December issue of Mayo Clinic Women’s HealthSource provides an overview of this sometimes embarrassing condition, what’s known about it and how it’s treated…
Also tagged Arthritis, Cardiovascular Disease, Chronic Disease, Healthsource, Mayo Clinic Women, Patches, Skin Disease, Systemic Disease
Study Redefines Placebo Effect As Part Of Effective Treatment
Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine…
Also tagged Medication, Medicine, Placebo Effect, Psoriasis Patients, Psychosomatic Medicine
Study Redefines Placebo Effect As Part Of Effective Treatment
Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine…
Also tagged Medication, Medicine, Placebo Effect, Psoriasis Patients, Psychosomatic Medicine
Positive Phase IIb Topline Clinical Data For Celgene Oral Compound Apremilast (CC-10004) Reported For Patients With Moderate-to-Severe Psoriasis
Celgene Corporation (NASDAQ:CELG) announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo…
Also tagged Celg, Double Blind Placebo, Nasdaq, Oral Compound, Phase Iib, Plaque Type, Psor
Provectus Announces Preliminary Phase 2 Data For PH-10 In Its Psoriasis And Atopic Dermatitis Trials
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis. Dr. Craig Dees, Ph.D…
Also tagged Atopic Dermatitis, Biopharmaceutical Company, Clinical Trial, Craig, Dermatitis, Dermatology, Development Stage, Oncology, Otc Bb, Pharmaceuticals Inc, Phase 10, Phase 2
